Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3′-azido-3′- deoxythymidine with nonnucleoside inhibitors

Biochemistry

Volumn 44, Issue 9, 2005, Pages 3535-3546

  Cruchaga, Carlos ^a   Odriozola, Leticia ^a   Andréola, Marieline ^b   Tarrago Litvak, Laura ^b   Martínez Irujo, Juan J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CELL CULTURE; CHEMOTHERAPY; DISEASE CONTROL; DNA;

PHOSPHOROLYSIS; PRIMERS; REPLICATION; REVERSE TRANSCRIPTASE (RT);

VIRUSES;

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; WILD TYPE;

BINDING SITES; CATALYSIS; DNA PRIMERS; DRUG COMBINATIONS; DRUG SYNERGISM; ENZYME STABILITY; HIV-1 REVERSE TRANSCRIPTASE; NEVIRAPINE; OXAZINES; PHOSPHORIC ACIDS; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; TEMPLATES, GENETIC; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 14644441681     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi048129z     Document Type: Article

References (52)

1. Richman, D. D. (2001) HIV chemotherapy, Nature 410, 995-1001.
2. Parker, W. B., White, E. L., Shaddix, S. C., Ross, L. J., Buckheit, R. W., Jr., Germany, J. M., Secrist, J. A., 3rd, Vince, R., and Shannon, W. M. (1991) Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′, 3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs, J. Biol. Chem. 266, 1754-1762.
3. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor, Science 256, 1783-1790.
4. Tantillo, C., Ding, J., Jacobo Molina, A., Nanni, R. G., Boyer, P. L., Hughes, S. H., Pauwels, R., Andries, K., Janssen, P. A., and Arnold, E. (1994) Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance, J. Mol. Biol. 243, 369-387.
5. Buckheit, R. W., Jr., Hollingshead, M., Stinson, S., Fliakas Boltz, V., Pallansch, L. A., Roberson, J., Decker, W., Elder, C., Borgel, S., Bonomi, C., Shores, R., Siford, T., Malspeis, L., and Bader, J. P. (1997) Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1, AIDS Res. Hum. Retroviruses 13, 789-796.
6. Goldman, M. E., Nunberg, J. H., O'Brien, J. A., Quintero, J. C., Schleif, W. A., Freund, K. F., Gaul, S. L., Saari, W. S., Wai, J. S., Hoffman, J. M., Anderson, P. S., Hupe, D. J., Emini, E. A., and Stern, A. M. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity, Proc. Natl. Acad. Sci. U.S.A. 88, 6863-6867.
7. Buckheit, R. W., Jr., White, E. L., Fliakas Boltz, V., Russell, J., Stup, T. L., Kinjerski, T. L., Osterling, M. C., Weigand, A., and Bader, J. P. (1999) Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide, Antimicrob. Agents Chemother. 43, 1827-1834.
8. Buckheit, R. W., Jr., Snow, M. J., Fliakas-Boltz, V., Kinjerski, T. L., Russell, J. D., Pallansch, L. A., Brouwer, W. G., and Yang, S. S. (1997) Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates, Antimicrob. Agents Chemother. 41, 831-837.
9. Richman, D., Rosenthal, A. S., Skoog, M., Eckner, R. J., Chou, T. C., Sabo, J. P., and Merluzzi, V. J. (1991) BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine, Antimicrob. Agents Chemother. 35, 305-308.
10. Chong, K. T., Pagano, P. J., and Hinshaw, R. R. (1994) Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro, Antimicrob. Agents Chemother. 38, 288-293.
11. Witvrouw, M., Arranz, M. E., Pannecouque, C., Declercq, R., Jonckheere, H., Schmit, J. C., Vandamme, A. M., Diaz, J. A., Ingate, S. T., Desmyter, J., Esnouf, R., Van Meervelt, L., Vega, S., Balzarini, J., and De Clercq, E. (1998) 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity, Antimicrob. Agents Chemother. 42, 618-623.
12. Buckheit, R. W., Jr., Hollingshead, M. G., Germany Decker, J., White, E. L., McMahon, J. B., Allen, L. B., Ross, L. J., Decker, W. D., Westbrook, L., Shannon, W. M., Weislow, O., Bader, J. P., and Boyd, M. R. (1993) Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor, Antiviral Res. 21, 247-265.
13. McMahon, J. B., Buckheit, R. W., Jr., Gulakowski, R. J., Currens, M. J., Vistica, D. T., Shoemaker, R. H., Stinson, S. F., Russell, J. D., Bader, J. P., Narayanan, V. L., Schultz, R. J., Brouwer, W. G., Felauer, E. E., and Boyd, M. R. (1996) Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor, J. Pharmacol. Exp. Ther. 276, 298-305.
14. Pauwels, R., Andries, K., Debyser, Z., Kukla, M. J., Schols, D., Breslin, H. J., Woestenborghs, R., Desmyter, J., Janssen, M. A., De Clercq, E., and Janssen, P. A. J., (1994) New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin- 2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs, Antimicrob. Agents Chemother. 38, 2863-2870.
15. Maga, G., Ramunno, A., Nacci, V., Locatelli, G. A., Spadari, S., Fiorini, I., Baldanti, F., Paolucci, S., Zavattoni, M., Bergamini, A., Galletti, B., Muck, S., Hubscher, U., Giorgi, G., Guiso, G., Caccia, S., and Campiani, G. (2001) The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors, J. Biol. Chem. 276, 44653-44662.
16. Borkow, G., Arion, D., Wainberg, M. A., and Parniak, M. A. (1999) The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1, Antimicrob. Agents Chemother. 43, 259-263.
17. Tramontano, E., and Cheng, Y. C. (1992) HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587, Biochem. Pharmacol. 43, 1371-1376.
18. Balzarini, J., Perez Perez, M. J., San Felix, A., Camarasa, M. J., Bathurst, I. C., Barr, P. J., and De Clercq, E. (1992) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide)-thymine (TSAO-T), J. Biol. Chem. 267, 11831-11838.
19. Villahermosa, M. L., Martinez Irujo, J. J., Cabodevilla, F., and Santiago, E. (1997) Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides, Biochemistry 36, 13223-13231.
20. Gu, Z., Quan, Y., Li, Z., Arts, E. J., and Wainberg, M. A. (1995) Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays, J. Biol. Chem. 270, 31046-31051.
21. Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., Carroll, S. S., Pettibone, D. J., O'Brien, J. A., Ball, R. G., Balani, S. K., Lin, J. H., Chen, I., Schleif, W. A., Sardana, V. V., Long, W. J., Byrnes, V. W., and Emini, E. A. (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother. 39, 2602-2605.
22. Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors, Science 267, 988-993.
23. Rittinger, K., Divita, G., and Goody, R. S. (1995) Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors, Proc. Natl. Acad. Sci. U.S.A. 92, 8046-8049.
24. Maga, G., Ubiali, D., Salvetti, R., Pregnolato, M., and Spadari, S. (2000) Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes, Antimicrob. Agents Chemother. 44, 1186-1194.
25. Carroll, S. S., Stahlhut, M., Geib, J., and Olsen, D. B. (1994) Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. Differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs, J. Biol. Chem. 269, 32351-32357.
26. King, R. W., Klabe, R. M., Reid, C. D., and Erickson-Viitanen, S. K. (2002) Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors, Antimicrob. Agents Chemother. 46, 1640-1646.
27. Odriozola, L., Cruchaga, C., Andreola, M., Dolle, V., Nguyen, C. H., Tarrago-Litvak, L., Perez-Mediavilla, A., and Martinez-Irujo, J. J. (2003) Nonnucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3′-azido-3′-deoxythymidine (AZT)-resistant polymerase to AZTTP, J. Biol. Chem. 278, 42710-42716.
28. Dolle, V., Nguyen, C. H., Legraverend, M., Aubertin, A. M., Kirn, A., Andreola, M. L., Ventura, M., Tarrago Litvak, L., and Bisagni, E. (2000) Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors, J. Med. Chem. 43, 3949-3962.
29. Basavapathruni, A., Bailey, C. M., and Anderson, K. S. (2004) Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs, J. Biol. Chem. 279, 6221-6224.
30. Kati, W. M., Johnson, K. A., Jerva, L. F., and Anderson, K. S. (1992) Mechanism and fidelity of HIV reverse transcriptase, J. Biol. Chem. 267, 25988-25997.
31. Tong, W., Lu, C. D., Sharma, S. K., Matsuura, S., So, A. G., and Scott, W. A. (1997) Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase, Biochemistry 36, 5749-5757.
32. Isel, C., Ehresmann, C., Walter, P., Ehresmann, B., and Marquet, R. (2001) The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild-type HIV-1 reverse transcriptase, J. Biol. Chem. 276, 48725-48732.
33. Muller, B., Restle, T., Reinstein, J., and Goody, R. S. (1991) Interaction of fluorescently labeled dideoxynucleotides with HIV-1 reverse transcriptase, Biochemistry 30, 3709-3715.
34. Berenbaum, M. C. (1978) A method for testing for synergy with any number of agents, J. Infect. Dis. 137, 122-130.
35. Yonetani, T., and Theorell, H. (1964) Studies on liver alcohol dehydrogenase complexes. III Multiple inhibition kinetics in the presence of two competitive inhibitors., Arch. Biochem. Biophys. 106, 243-251.
36. Martinez-Irujo, J. J., Villahermosa, M. L., Alberdi, E., and Santiago, E. (1996) A checkerboard method to evaluate interactions between drugs, Biochem. Pharmacol. 51, 635-644.
37. Goody, R. S., Muller, B., and Restle, T. (1991) Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo, FEBS Lett. 291, 1-5.
38. Huang, Y., Mak, J., Cao, Q., Li, Z., Wainberg, M. A., and Kleiman, L. (1994) Incorporation of excess wild-type and mutant tRNA-(3Lys) into human immunodeficiency virus type 1, J. Virol. 68, 7676-7683.
39. Meyer, P. R., Matsuura, S. E., So, A. G., and Scott, W. A. (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism, Proc. Natl. Acad. Sci. U.S.A. 95, 13471-13476.
40. Rigourd, M., Ehresmann, C., Parniak, M. A., Ehresmann, B., and Marquet, R. (2002) Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesis, J. Biol. Chem. 277, 18611-18618.
41. Maga, G., Hubscher, U., Pregnolato, M., Ubiali, D., Gosselin, G., and Spadari, S. (2001) Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs, Antimicrob. Agents Chemother. 45, 1192-1200.
42. Fletcher, R. S., Arion, D., Borkow, G., Wainberg, M. A., Dmitrienko, G. I., and Parniak, M. A. (1995) Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds, Biochemistry 34, 10106-10112.
43. Barnard, J., Borkow, G., and Parniak, M. A. (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase, Biochemistry 36, 7786-7792.
44. Zhang, H., Vrang, L., Backbro, K., Lind, P., Sahlberg, C., Unge, T., and Oberg, B. (1995) Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127, Antiviral Res. 28, 331-342.
45. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G., and Scott, W. A. (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase, Mol. Cell. 4, 35-43.
46. Matamoros, T., Franco, S., Vazquez-Alvarez, B. M., Mas, A., Martinez, M. A., and Menendez-Arias, L. (2004) Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers, J. Biol. Chem. 279, 24569-24577.
47. Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2001) Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase, J. Virol. 75, 4832-4842.
48. Ray, A. S., Murakami, E., Basavapathruni, A., Vaccaro, J. A., Ulrich, D., Chu, C. K., Schinazi, R. F., and Anderson, K. S. (2003) Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis, Biochemistry 42, 8831-8841.
49. Reardon, J. E. (1993) Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization, J. Biol. Chem. 268, 8743-8751.
50. Velazquez, S., Alvarez, R., San Felix, A., Jimeno, M. L., De Clercq, E., Balzarini, J., and Camarasa, M. J. (1995) Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase, J. Med. Chem. 38, 1641-1649.
51. Pontikis, R., Dolle, V., Guillaumel, J., Dechaux, E., Note, R., Nguyen, C. H., Legraverend, M., Bisagni, E., Aubertin, A. M., Grierson, D. S., and Monneret, C. (2000) Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase, J. Med. Chem. 43, 1927-1939.
52. Gavriliu, D., Fossey, C., Ciurea, A., Delbederi, Z., Sugeac, E., Laduree, D., Schmidt, S., Laumond, G., and Aubertin, A. M. (2002) Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase, Nucleosides Nucleotides Nucleic Acids 21, 505-533.